Celator(R) Pharmaceuticals To Present at 2008 BIO Inve... ( PRINCETON N.J. Oct. 23 /- Celator...)

Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum

Date:10/23/2008

PRINCETON, N.J., Oct. 23 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the BIO Investor Forum in San Francisco. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentation will be held on Wednesday, October 29, 2008 at 1:45 PM PDT in the Marina Room of the Palace Hotel.

The company is also pleased to announce that Dr. Arthur Louie, chief medical officer, has been invited to participate in a therapeutic workshop titled, "Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon." The workshop will be held on Thursday, October 30, 2008 at 9:30 AM PDT in the Twin Peak South Room of the Palace Hotel.

About Celator

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with advanced leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http:/
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
2. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
3. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
7. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
8. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
10. Amylin Pharmaceuticals Reports Third Quarter Financial Results
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Post Your Comments:

(Date:11/9/2009).... 9 NexBio, Inc. announced the pre...College of Allergy, Asthma, and Immunology in Miam... (Fludase®), a Sialidase, Decreases Airway Re...in Animal Models of Asthma". ,, DAS181 (Fludase...t-targeting drug candidate being studied in human ...

(Date:11/9/2009)...vember 9 Following the provision o...Drug Administration (FDA), privately,owned UK comp...international.com ) has been informed that its inn...n awarded an Orphan-Drug,designation for the treat..., ALS, also known as Lou Gehrig,s disease, is ...

(Date:11/6/2009)...6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc...iled the Form 52-109F1 Certification of Annual Fil...r and James Long, the Chief Financial Officer (the...in connection with the annual audited financial st..., The Company initially filed the annual financi...

(Date:11/6/2009)...stria, November 6 EUCODIS Bioscien...ng, and marketing enzymes for the,chemical industr...rch,agreement with Bio Sidus, the leading biopharm... agreement gives EUCODIS Bioscience exclusive acce...o Sidus, proprietary collection of,psychrophilic b...

Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2 NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3 EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2

[0] NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 [0] Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment [1] Microbix Biosystems Re-files Annual Results With OSC [0] EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus

...ed for the First Time on 50 mg/Day Dose for PRISTI...ssive Disorder, COLLEGEVILLE, Pa., Dec. 12 Wyeth...), announces that data from,two Phase 3 clinical s...gational serotonin-norepinephrine reuptake inhibit... a 50 mg/day dose of PRISTIQ for the,treatment of ...

...he Netherlands, December 12 , - Forty-five Presti...Response to Customer Demand, Elsevier, a leading ...M) information, today announced that 45 French-lan...e available on ScienceDirect beginning January,3, ...gie, Journal de Chirurgie and,La Press Medicale, r...

...IND has Been Filed With the FDA for the Fourth Gen...Collaboration with Roche., COPENHAGEN, December 1...nvestigational New Drug application (IND) for a,Ge...oration with Roche has,been filed with the FDA by ...velopment of the antibody which selectively blocks...

Other Biology Technology:New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2 New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3 New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4 New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5 New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6 ScienceDirect to Host French-Language Journals from Elsevier Masson 2 ScienceDirect to Host French-Language Journals from Elsevier Masson 3 Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2 Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3

New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo ScienceDirect to Host French-Language Journals from Elsevier Masson Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic

(Date:11/4/2009)...t Norman has received more than $10 million in res... the federal stimulus program, bringing thetotal a...rs to $23 million. Thirty-three projects achieved...logy to weather. , "The university has thoughtfu...reasof scholarly excellence to federal agency prio...

(Date:11/4/2009)...PRNewswire-FirstCall/ -- Quest Diagnostics Incorpo...of diagnostic testing, information and services, a...r 30, 2009, income from continuing operations rose... $160 million, or $0.81 per diluted share, for the...ults were reduced by a $0.03 per share charge asso...

(Date:11/4/2009)... Aware, Inc. (Nasdaq: AW...nd biometrics software, today reported financial r...2009. ,, Michael Tzannes, Aware,s Chairman an...e announced an agreement to sell our DSL and home ...semiconductor company being spun out of Infineon. ...

[0] OU achieves $10 million in stimulus grants for 33 projects on the Norman campus [0] Quest Diagnostics Reports Strong Performance in Third Quarter 2009 [0] Aware, Inc. Reports Third Quarter 2009 Financial Results

...rrow Neurological Institute at St. Joseph,s Hospit...k between eye motions and the perception of illuso...Stephen Macknik, PhD, director of the Laboratory o...e, PhD, director of the Laboratory of Visual Neuro...illan; conducted a study based on the Enigma paint...

... have grown soybeans and turned them into many use...hy a soybean grows, blooms or produces like it doe... , University of Georgia professor Wayne Parrott...million grant from the National Science Foundation...ue. , "I,m convinced that soybeans would be so mu...

... city dwellers posed by Southern California wildfi...restimated by officials. , Detailed particulate a...ia wild fires indicates that the composition posed...generally realized, according to a new paper analy...thern California. , The paper, entitled "Physico...

Other Biology News:Soybean grant gives researchers tools to unravel better bean 2 Where there's wildfire smoke, there's toxicity 2

Barrow scientists solve 200-year-old scientific debate involving visual illusions Soybean grant gives researchers tools to unravel better bean Where there's wildfire smoke, there's toxicity

Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich

Nutrient Mixture F-12 Ham, Coon's Modification (Ham's F-12 Coon's) from Sigma-Aldrich

...solution is an isotonic, balanced salt solution. I...ervative, which permits the storage of whole blood... weeks.1 For usage, an equal volume of blood is co...y, but thoroughly, mixed. The solution is placed i...

...Mix or individual RNA sequences from high throughp...om small RNAs from LC Sciences. These products pro...ons) of DESIGNED sequences delivered in a microtub...taining a single verified RNA sequence. This is a ...

Biology Products:

Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich Nutrient Mixture F-12 Ham, Coon's Modification (Ham's F-12 Coon's) from Sigma-Aldrich Alsever's Solution from Sigma-Aldrich RNA OligoMix from LC Sciences

Celator(R) Pharmaceuticals To Present at 2008 BIO Inve...( PRINCETON N.J. Oct. 23 /- Celator...)